Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-07-11
2010-12-28
Whiteman, Brian (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07858593
ABSTRACT:
The invention relates to the field of muscle pathologies, more particularly to the field of diseases where skeletal muscle degeneration occurs. The invention describes transgenic mice that do not produce prolyl-hydroxylase-1, -2 or -3. It is revealed that the phenotype of the prolyl-hydroxylase 1 knock-out mouse is characterized by a protection of skeletal muscle atrophy due to a variety of muscle damages, especially ischemic insults. The invention thus relates to the use of molecules that can bind to prolyl-hydroxylase-1 for the prevention and/or treatment of skeletal muscle degeneration.
REFERENCES:
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 2004/0146964 (2004-07-01), Maxwell et al.
patent: 2004/0204356 (2004-10-01), Guenzler-Pukall et al.
patent: 2004/0254215 (2004-12-01), Arend et al.
patent: 2005/0119243 (2005-06-01), Harris et al.
patent: 2006/0216295 (2006-09-01), Crabtree et al.
patent: WO 94/01131 (1994-01-01), None
patent: WO 94/04672 (1994-03-01), None
patent: WO 94/04678 (1994-03-01), None
patent: WO 94/25591 (1994-11-01), None
patent: WO 97/49805 (1997-12-01), None
patent: WO 99/14220 (1999-03-01), None
patent: WO 02/074981 (2002-09-01), None
Mason et al. (PLOS Biology 2:1540-1548, 2004).
Epstein et al., C. Elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation, Cell, Oct. 5, 2001, pp. 43-54, vol. 107, No. 1.
Appeloff et al., Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor, Journal of Biological Chemistry, Sep. 10, 2004, pp. 38458-38465, vol. 279, No. 37.
Takeda et al., Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2, Molecular and Cellular Biology, Nov. 2006, pp. 8336-8346, vol. 26, No. 22.
Erez et al., Hypoxia-dependent regulation of PHD1: Cloning and Characterization of the human PHD1/EGLN2 gene promoter, FEBS Letters, Jun. 4, 2004, pp. 311-315, vol. 567, No. 2-3.
Bruick et al., A conserved family of prolyl-4-hydroxylases that modify HIF, Science, Nov. 9, 2001, pp. 1337-1340, vol. 294, No. 5545.
U.S. Appl. No. 12/459,463, filed Jul. 1, 2009, Inventor: Carmeliet et al., Title: Means and Methods for the Recruitment and Identification of Stem Cells.
U.S. Appl. No. 61/341,432, filed Mar. 30, 2010, Inventor: Mazzone et al., Title: Induction of Arteriogenesis by Cell Therapy With Polarized Myeloid Cells.
U.S. Appl. No. 12/658,284, filed Feb. 10, 2010, Inventor: Peter Carmeliet, Title: Treatment of Amyotrophic Lateral Sclerosis.
Carmeliet Peter
López Julián Aragonés
Life Sciences Research Partners VZW
TraskBritt P.C.
VIB VZW
Whiteman Brian
LandOfFree
Inhibitors of prolyl-hydroxylase-1 for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of prolyl-hydroxylase-1 for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of prolyl-hydroxylase-1 for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4171739